The product is intended to treat multiple myeloma and will be launched with a unique J-code in the second quarter of next year. Credit: Nemes Laszlo/Shutterstock.

The US Food and Drug Administration (FDA) has approved and Shilpa Medicare鈥檚 oncology product BORUZU for subcutaneous administration.

BORUZU, the first ready-to-use version of bortezomib, is a proteasome inhibitor indicated to treat multiple myeloma and mantle cell lymphoma.

Go deeper with GlobalData

  • ReportsLogo

  • ReportsLogo

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

The new product simplifies the preparation process compared to the currently available lyophilised powder form, which requires reconstitution before administration.

BORUZU references Velcade, the branded lyophilised powder version of bortezomib.

Developed by Shilpa, BORUZU will be manufactured and commercialised by Amneal.

See Also:

The product will be launched with a unique J-code [alphanumeric codes used for non-oral medications] in the second quarter of 2025.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Amneal Pharmaceuticals biosimilars and branded oncology vice-president Sean McGowan stated: 鈥淲e are building a distinct branded oncology injectable portfolio. The approval of BORUZU is our fourth 505(b)(2) injectable approval this year.

鈥淭hese ready-to-use injectable presentations are important innovations for oncology providers as they reduce the pharmacy preparation steps for clinicians. We look forward to bringing more branded oncology products to the market for providers while expanding access for patients.鈥�

In clinical studies, the most commonly reported adverse reactions linked to BORUZU treatment were anaemia, anorexia, asthenic conditions, constipation, decreased appetite, diarrhoea, leukopenia, nausea, neuralgia, neutropenia, peripheral neuropathy, psychiatric disorders, pyrexia, thrombocytopenia and vomiting.

Shilpa Medicare managing director Vishnukant Bhutada stated: 鈥淭his second NDA approval in the US market from our novel injectable portfolio is a testament to our capabilities and commitment to introducing pharmacy-efficient solutions that enhance preparation and have the potential to reduce patient wait times.

鈥淭his development exemplifies Shilpa鈥檚 constant endeavour to work towards introducing novel first-of-its-kind pharmaceutical products that help improve the healthcare requirements of a large patient pool.鈥�

In August 2024, the FDA approved Amneal Pharmaceuticals鈥� CREXONT extended-release capsules for Parkinson鈥檚 disease treatment.